Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

HIV Viral Load and Transmissibility of HIV Infection

(2019) Robert W. Eisinger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

(2019) Gregory D Huhn et al.   Open Forum Infectious Diseases

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

(2018) Joseph J. Eron et al.   AIDS

Linkage and Antiretroviral Therapy Within 72 Hours at a Federally Qualified Health Center in New Orleans

(2018) Jason Halperin et al.   AIDS PATIENT CARE AND STDS

Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho

(2018) Niklaus D. Labhardt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States

(2018) Jonathan Colasanti et al.   Open Forum Infectious Diseases

Prevalence of darunavir resistance in the United States from 2010 to 2017

(2018) Kimberley Brown et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Patient-Reported Outcomes in First-Line Antiretroviral Therapy

(2018) Elizabeth C George et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RAPID ART

(2018) Susa Coffey et al.   AIDS

A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV

(2018) Patrick G. Clay et al.   AIDS Research and Therapy

541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging

(2018) Christoph D Spinner et al.   Open Forum Infectious Diseases

HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies

(2017) Erkki Lathouwers et al.   HIV CLINICAL TRIALS

Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial

(2017) Serena P. Koenig et al.   PLOS MEDICINE

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

(2017) Chloe Orkin et al.   Lancet HIV

Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy

(2016) S. Scott Sutton et al.   PHARMACOTHERAPY

Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial

(2016) Sydney Rosen et al.   PLOS MEDICINE

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET